Suppr超能文献

细胞周期通路基因的遗传变异可预测肝细胞癌的无病生存期。

Genetic variants of cell cycle pathway genes predict disease-free survival of hepatocellular carcinoma.

作者信息

Liu Shun, Yang Tian-Bo, Nan Yue-Li, Li An-Hua, Pan Dong-Xiang, Xu Yang, Li Shu, Li Ting, Zeng Xiao-Yun, Qiu Xiao-Qiang

机构信息

Department of Epidemiology, School of Public Health, Guangxi Medical University, 22 Shuangyong Road, Nanning, Guangxi, 530021, China.

Affiliated Tumor Hospital of Guangxi Medical University, 71 Hedi Road, Nanning, Guangxi, 530021, China.

出版信息

Cancer Med. 2017 Jul;6(7):1512-1522. doi: 10.1002/cam4.1067. Epub 2017 Jun 22.

Abstract

Disruption of the cell cycle pathway has previously been related to development of human cancers. However, associations between genetic variants of cell cycle pathway genes and prognosis of hepatocellular carcinoma (HCC) remain largely unknown. In this study, we evaluated the associations between 24 potential functional single nucleotide polymorphisms (SNPs) of 16 main cell cycle pathway genes and disease-free survival (DFS) of 271 HCC patients who had undergone radical surgery resection. We identified two SNPs, i.e., SMAD3 rs11556090 A>G and RBL2 rs3929G>C, that were independently predictive of DFS in an additive genetic model with false-positive report probability (FPRP) <0.2. The SMAD3 rs11556090G allele was associated with a poorer DFS, compared with the A allele [hazard ratio (HR) = 1.46, 95% confidential interval (95% CI) = 1.13-1.89, P = 0.004]; while the RBL2 rs3929 C allele was associated with a superior DFS, compared with the G allele (HR = 0.74, 95% CI = 0.57-0.96, P = 0.023). Additionally, patients with an increasing number of unfavorable genotypes (NUGs) of these loci had a significant shorter DFS (P  = 0.0001). Further analysis using receiver operating characteristic (ROC) curves showed that the model including the NUGs and known prognostic clinical variables demonstrated a significant improvement in predicting the 1-year DFS (P = 0.011). Moreover, the RBL2 rs3929 C allele was significantly associated with increased mRNA expression levels of RBL2 in liver tissue (P = 1.8 × 10 ) and the whole blood (P = 3.9 × 10 ). Our data demonstrated an independent or a joint effect of SMAD3 rs11556090 and RBL2 rs3929 in the cell cycle pathway on DFS of HCC, which need to be validated by large cohort and biological studies.

摘要

细胞周期途径的破坏此前已被证明与人类癌症的发生有关。然而,细胞周期途径基因的遗传变异与肝细胞癌(HCC)预后之间的关联在很大程度上仍不清楚。在本研究中,我们评估了16个主要细胞周期途径基因的24个潜在功能性单核苷酸多态性(SNP)与271例接受根治性手术切除的HCC患者无病生存期(DFS)之间的关联。我们鉴定出两个SNP,即SMAD3基因的rs11556090 A>G和RBL2基因的rs3929G>C,在假阳性报告概率(FPRP)<0.2的加性遗传模型中,它们可独立预测DFS。与A等位基因相比,SMAD3基因的rs11556090G等位基因与较差的DFS相关[风险比(HR)=1.46,95%置信区间(95%CI)=1.13-1.89,P=0.004];而与G等位基因相比,RBL2基因的rs3929 C等位基因与较好的DFS相关(HR=0.74,95%CI=0.57-0.96,P=0.023)。此外,这些位点的不良基因型数量(NUGs)增加的患者DFS显著缩短(P=0.0001)。使用受试者工作特征(ROC)曲线进行的进一步分析表明,包含NUGs和已知预后临床变量的模型在预测1年DFS方面有显著改善(P=0.011)。此外,RBL2基因的rs3929 C等位基因与肝组织中RBL2的mRNA表达水平升高显著相关(P=1.8×10)以及全血中RBL2的mRNA表达水平升高显著相关(P=3.9×10)。我们的数据表明,细胞周期途径中SMAD3基因的rs11556090和RBL2基因的rs3929对HCC的DFS具有独立或联合作用,这需要通过大规模队列研究和生物学研究来验证。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9380/5504311/19a60e17a315/CAM4-6-1512-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验